{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:11:15Z","timestamp":1762431075713},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.gastrohep.2015.08.003","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T00:23:20Z","timestamp":1446683000000},"page":"282-292","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Papel de la rifaximina en el tratamiento de la encefalopat\u00eda hep\u00e1tica"],"prefix":"10.1016","volume":"39","author":[{"given":"Jordi","family":"Sanchez-Delgado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Miquel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5 Pt 2","key":"10.1016\/j.gastrohep.2015.08.003_bib0320","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1592\/phco.30.pt2.10S","article-title":"Clinical management of hepatic encephalopathy","volume":"30","author":"Schiano","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0325","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"issue":"Suppl2","key":"10.1016\/j.gastrohep.2015.08.003_bib0330","first-page":"74","article-title":"Hepatic encephalopathy","volume":"37","author":"Cordoba","year":"2014","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0335","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathy \u2014 definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998","volume":"35","author":"Ferenci","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0340","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrgastro.2010.116","article-title":"Mechanisms, diagnosis and management of hepatic encephalopathy","volume":"7","author":"Prakash","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0345","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/ajg.2009.738","article-title":"Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: A study on the pathophysiology of hepatic encephalopathy","volume":"105","author":"Riggio","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0350","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMe1000850","article-title":"Gut flora and hepatic encephalopathy in patients with cirrhosis","volume":"362","author":"Riordan","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0355","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s00018-005-5089-0","article-title":"The pathophysiologic basis of hepatic encephalopathy: Central role for ammonia and inflammation","volume":"62","author":"Shawcross","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0360","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1023\/B:MEBR.0000043980.74574.eb","article-title":"Blood ammonia levels and hepatic encephalopathy","volume":"19","author":"Lockwood","year":"2004","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0365","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.21533","article-title":"Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy","volume":"45","author":"Prasad","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0370","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/bmj.38048.506134.EE","article-title":"Non-absorbable disaccharides for hepatic encephalopathy: Systematic review of randomised trials","volume":"328","author":"Als-Nielsen","year":"2004","journal-title":"BMJ"},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2015.08.003_bib0375","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000089776","article-title":"Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic","volume":"73","author":"Scarpignato","year":"2006","journal-title":"Digestion"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0380","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11011-013-9383-5","article-title":"Antibiotics for the treatment of hepatic encephalopathy","volume":"28","author":"Patidar","year":"2013","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0385","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/apt.12993","article-title":"Prolonged remission from hepatic encephalopathy with rifaximin: Results of a placebo crossover analysis","volume":"41","author":"Bajaj","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0390","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/apt.13122","article-title":"Systematic review with network meta-analysis: The comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy","volume":"41","author":"Zhu","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2015.08.003_bib0395","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","article-title":"Rifaximin: In vitro and in vivo antibacterial activity\u2014a review","volume":"51","author":"Jiang","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0400","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/hep.23866","article-title":"Drug therapy: Rifaximin","volume":"52","author":"Bajaj","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0405","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4292\/wjgpt.v3.i4.62","article-title":"Rifaximin therapy and hepatic encephalopathy: Pros and cons","volume":"3","author":"Zullo","year":"2012","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0410","doi-asserted-by":"crossref","first-page":"G675","DOI":"10.1152\/ajpgi.00152.2012","article-title":"Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation","volume":"303","author":"Bajaj","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0415","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jhep.2010.05.002","article-title":"Rifaximin in hepatic encephalopathy: More than just a non-absorbable antibiotic?","volume":"53","author":"Jalan","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0420","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","article-title":"Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites","volume":"10","author":"Kalambokis","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0425","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1179\/joc.2002.14.3.290","article-title":"Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis","volume":"14","author":"Brigidi","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0430","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MCG.0b013e318276be13","article-title":"Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: A retrospective analysis","volume":"47","author":"Neff","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0435","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0440","doi-asserted-by":"crossref","first-page":"e60042","DOI":"10.1371\/journal.pone.0060042","article-title":"Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy","volume":"8","author":"Bajaj","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0445","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.cgh.2013.12.021","article-title":"Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy","volume":"12","author":"Mullen","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0450","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1345\/aph.1P578","article-title":"Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth","volume":"45","author":"Hoffman","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0455","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/ajg.2013.219","article-title":"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy","volume":"108","author":"Sharma","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0460","first-page":"11","article-title":"Review: Rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy","volume":"149","author":"Alcorn","year":"2008","journal-title":"ACP J Club"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0465","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1185\/03007999309111539","article-title":"Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy","volume":"13","author":"Bucci","year":"1993","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0470","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10620-006-9442-4","article-title":"Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy","volume":"52","author":"Leevy","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0475","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-8278(02)00350-1","article-title":"Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial","volume":"38","author":"Mas","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0480","first-page":"668","article-title":"Rifaximina in collateral treatment of porto-systemic encephalopathy: A preliminary report","volume":"36","author":"De Marco","year":"1984","journal-title":"Current Therapeutic Research"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0485","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0011-393X(05)80433-3","article-title":"Effect of Rifaximin and Paramomycin in the treatment of portal-systemic encephalopathy","volume":"52","author":"Parini","year":"1992","journal-title":"Current Therapeutic Research"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0490","first-page":"407A","article-title":"The clinical efficacy of rifaximin in the treatment of hepatic encephalopathy (comparison with lactulose)","volume":"32","author":"Song","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0495","first-page":"646A","article-title":"Rifaximin treatment is beneficial for mild hepatic encephalopathy","volume":"40","author":"Bass","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0500","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3349\/ymj.2005.46.3.399","article-title":"Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: A prospective randomized study","volume":"46","author":"Paik","year":"2005","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0505","doi-asserted-by":"crossref","DOI":"10.1177\/0897190014566312","article-title":"Treatment of acute hepatic encephalopathy: Comparing the effects of adding Rifaximin to Lactulose on patient outcomes","author":"Courson","year":"2015","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0510","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0011-393X(05)80681-2","article-title":"Rifaximin in the treatment of chronic hepatic encephalopathy; Results of a multicenter study of efficacy and safety","volume":"54","author":"Festi","year":"1993","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0515","first-page":"53","article-title":"Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study","volume":"49","author":"Loguercio","year":"2003","journal-title":"Minerva Gastroenterol Dietol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0520","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1185\/03007999709113333","article-title":"Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial","volume":"13","author":"Miglio","year":"1997","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0525","first-page":"175","article-title":"Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial","volume":"23","author":"Pedretti","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0530","first-page":"269","article-title":"Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver","volume":"24","author":"Ali","year":"2014","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0535","first-page":"1021","article-title":"Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis","volume":"116","author":"Irimia","year":"2012","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0540","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/jgh.12970","article-title":"Comparison of once a day rifaximin to twice a day dosage in prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease","volume":"30","author":"Khokhar","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0545","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/j.transproceed.2006.10.107","article-title":"Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy","volume":"38","author":"Neff","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0550","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/MCG.0b013e318231faae","article-title":"Durability of rifaximin response in hepatic encephalopathy","volume":"46","author":"Neff","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0555","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2004.12.028","article-title":"Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled study","volume":"42","author":"Riggio","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0560","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/gutjnl-2014-308521","article-title":"Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed","volume":"64","author":"Maharshi","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0565","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11011-014-9507-6","article-title":"Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in cirrhosis: Implications for the gut-liver-brain axis","volume":"29","author":"Ahluwalia","year":"2014","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0570","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.gastro.2010.08.061","article-title":"Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy","volume":"140","author":"Bajaj","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0575","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2036.2011.04808.x","article-title":"Randomised clinical trial: Rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy \u2014 a double-blind placebo-controlled study","volume":"34","author":"Sanyal","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0580","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/1319-3767.136975","article-title":"Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial","volume":"20","author":"Sharma","year":"2014","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0585","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ajg.2010.455","article-title":"Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME trial)","volume":"106","author":"Sidhu","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0590","first-page":"2954","article-title":"Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis","volume":"8","author":"Zhang","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0595","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/apt.12803","article-title":"Systematic review with meta-analysis: The effects of rifaximin in hepatic encephalopathy","volume":"40","author":"Kimer","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0600","doi-asserted-by":"crossref","first-page":"236963","DOI":"10.1155\/2013\/236963","article-title":"Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: A meta-analysis","volume":"2013","author":"Wu","year":"2013","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0605","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","article-title":"Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites","volume":"10","author":"Kalambokis","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0610","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.2214\/AJR.09.2968","article-title":"Management of refractory hepatic encephalopathy after insertion of TIPS: Long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft","volume":"193","author":"Fanelli","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0615","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s40265-014-0300-y","article-title":"Rifaximin: A review of its use in reducing recurrence of overt hepatic encephalopathy episodes","volume":"74","author":"Scott","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0620","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1365-2036.2007.03464.x","article-title":"The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy \u2014 a decision analysis","volume":"26","author":"Huang","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2015.08.003_bib0625","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1365-2036.2010.04257.x","article-title":"Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients","volume":"31","author":"Bajaj","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"5 Pt 2","key":"10.1016\/j.gastrohep.2015.08.003_bib0630","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1592\/phco.30.pt2.22S","article-title":"Factors affecting compliance and persistence with treatment for hepatic encephalopathy","volume":"30","author":"Neff","year":"2010","journal-title":"Pharmacotherapy"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570515002113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570515002113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T06:54:22Z","timestamp":1718175262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570515002113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0210570515002113"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2015.08.003","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Papel de la rifaximina en el tratamiento de la encefalopat\u00eda hep\u00e1tica","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2015.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and AEEH y AEG. All rights reserved.","name":"copyright","label":"Copyright"}]}}